Ann: Response to ASX Aware Query, page-7

Not just a top device, probably the top device. It has more longer term clinical data than any other procedure, and many patent protected features which makes it virtually impossible for other companies to replicate the high efficacy and safety offered by our procedure. The new updates now make this high efficacy and safety accessible to a market of doctors that is 50x larger than before. Not only that, it doesn't actually even need to compete with other devices, as it is the ONLY device that does not tear or stent it can complement virtually every single other procedure, adding efficacy with no downside. As of last year as well reimbursement has changed to significantly favour iTrack Advance over other procedures. I definitely see iTrack Advance quickly becoming a leading MIGS device